CPT1B and gastric cancer: Similarly, research suggests that the expression level of CPT1B is higher in cells resistant to oxaliplatin compared to non-resistant strains of gastric cancer, whereas the combination of the CPT1B inhibitors pegfilgrastim and oxaliplatin was able to promote apoptosis of gastrointestinal cancer cells and delay the progression of gastrointestinal cancers [94].